Leading Cancer Researcher: They’re Ignoring My Research, Cancer Patients Must Know This!

Cancer functions as a mitochondrial metabolic disease rather than a purely genetic one, driven by irreversible damage to the cell's energy-producing organelles. When mitochondria falter, cells revert to ancient, inefficient fermentation pathways fueled by glucose and glutamine, triggering the dysregulated growth characteristic of tumors. Monitoring the Glucose Ketone Index (GKI) provides a vital biomarker for mitochondrial health, with a low GKI indicating a protective state that starves cancer cells of their primary energy sources. Integrating metabolic therapies—such as ketogenic diets and fasting—alongside conventional treatments can protect healthy cells and sensitize tumors to lower, more effective doses of chemotherapy. This bioenergetic approach challenges the mainstream somatic mutation theory, offering a strategy to manage aggressive cancers like glioblastoma by targeting the metabolic vulnerabilities of the tumor rather than focusing solely on DNA mutations.